NCT00109317已完成3 期
A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 686
研究概览
简要总结
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Plaque psoriasis covering >=10% of total BSA
- •Diagnosis of plaque psoriasis for at least 6 months
- •Minimal PASI score of 12.0 at screening
- •In the opinion of the investigator, candidate for systemic therapy for psoriasis who has not been previously treated (naive to systemic treatment) or prior treatment with systemic therapy for psoriasis (e.g., PUVA, cyclosporine, corticosteroids, methotrexate, oral retinoids, MMF, thioguanine, hydroxyurea, sirolimus, azathioprine, 6-MP, etanercept)
- •Body weight of <=140 kg
- •18 to 75 years old
- •For women of childbearing potential, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study
- •Willingness to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources during the study
- •Willingness to enter Study ACD2601g
排除标准
- •Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
- •History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies or fusion proteins that contain an Ig Fc region
- •Clinically significant psoriasis flare during screening or on the day of randomization
- •History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
- •History of opportunistic infections (e.g., systemic fungal infections, parasites)
- •Seropositivity for human immunodeficiency virus (HIV)
- •Pregnancy or lactation
- •WBC count <4000/uL or >14,000/uL
- •Seropositivity for hepatitis B or C virus
- •Hepatic enzymes >=3x the upper limits of normal (ULN)
- •History of active tuberculosis (TB) or currently undergoing treatment for TB
- •Presence of malignancy within the past 5 years, including lymphoproliferative disorders
- •Previous treatment with efalizumab (anti-CD11a)
- •Diagnosis of hepatic cirrhosis, regardless of cause or severity
- •Serum creatinine >=2x the ULN
- •Hospital admission for cardiac disease, stroke, or pulmonary disease within the last year
- •History of substance abuse within the last 5 years
- •Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug
研究组 & 干预措施
未命名试验
干预措施: Raptiva (efalizumab) (Drug)
研究者
相似试验
已完成
3 期
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With AsthmaModerate to Severe AsthmaNCT05062759AstraZeneca70
终止
3 期
A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)Systemic Lupus ErythematosusNCT00539838Genentech, Inc.33
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT05743075Nuance Pharma (shanghai) Co., Ltd526
已完成
3 期
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant HypertensionResistant HypertensionNCT06168409AstraZeneca218
终止
3 期
A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)Lupus NephritisSystemic Lupus ErythematosusNCT00626197Genentech, Inc.381